Capricor Therapeutics reported $-7832000 in Operating Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Bioline Rx BLRX:US $ -6.08M 0.52M
Bluebird Bio BLUE:US $ -107.4M 12.95M
Capricor Therapeutics CAPR:US $ -7.83M 1.44M
Cytokinetics CYTK:US $ -10.87M 69.68M
Cytori Therapeutics CYTX:US $ -5120000 1.19M
Geron GERN:US $ -28.68M 2.31M
Johnson & Johnson JNJ:US $ 5840M 22M
Newlink Genetics NLNK:US -7731000 1.16M
Prothena PRTA:US -37944000 4.85M
Ptc Therapeutics PTCT:US $ -92.36M 5.84M
Sarepta Therapeutics SRPT:US $ -211.13M 124.25M
Vascular Biogenics VBLT:US -10564000 1.45M
Vital Therapies VTL:US $ -21.44M 0.29M